investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma PRINCETON, NJ . & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, IncRead more
- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of itsRead more
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positiveRead more